{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:03:52Z","timestamp":1773921832175,"version":"3.50.1"},"reference-count":37,"publisher":"The Endocrine Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,2,1]]},"abstract":"<jats:p>Human anaplastic thyroid cancer (ATC) is a lethal disease with an advanced clinical presentation and median survival of 3 months. The BRAFV600E oncoprotein is a potent transforming factor that causes human thyroid cancer cell progression in vitro and in vivo; therefore, we sought to target this oncoprotein in a late intervention model of ATC in vivo. We used the human ATC cell line 8505c, which harbors the BRAFV600E and TP53R248G mutations. Immunocompromised mice were randomized to receive the selective anti-BRAFV600E inhibitor, PLX4720, or vehicle by oral gavage 28 d after tumor implantation, 1 wk before all animals typically die due to widespread metastatic lung disease and neck compressive symptoms in this model. Mice were euthanized weekly to evaluate tumor volume and metastases. Control mice showed progressive tumor growth and lung metastases by 35 d after tumor implantation. At that time, all control mice had large tumors, were cachectic, and were euthanized due to their tumor-related weight loss. PLX4720-treated mice, however, showed a significant decrease in tumor volume and lung metastases in addition to a reversal of tumor-related weight loss. Mouse survival was extended to 49 d in PLX4720-treated animals. PLX4720 treatment inhibited cell cycle progression from 28 d to 49 d in vivo. PLX4720 induces striking tumor regression and reversal of cachexia in an in vivo model of advanced thyroid cancer that harbors the BRAFV600E mutation.<\/jats:p>","DOI":"10.1210\/en.2011-1519","type":"journal-article","created":{"date-parts":[[2011,12,27]],"date-time":"2011-12-27T21:15:39Z","timestamp":1325020539000},"page":"985-994","source":"Crossref","is-referenced-by-count":49,"title":["Late Intervention with anti-BRAFV600E Therapy Induces Tumor Regression in an Orthotopic Mouse Model of Human Anaplastic Thyroid Cancer"],"prefix":"10.1210","volume":"153","author":[{"given":"Matthew A.","family":"Nehs","sequence":"first","affiliation":[{"name":"Thyroid Cancer Research Laboratory (M.A.N., C.N., S.S.N., D.M.-G., R.A.H. S.P.), Endocrine Surgery Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"}]},{"given":"Carmelo","family":"Nucera","sequence":"first","affiliation":[{"name":"Thyroid Cancer Research Laboratory (M.A.N., C.N., S.S.N., D.M.-G., R.A.H. S.P.), Endocrine Surgery Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Cancer Biology and Angiogenesis (C.N.), Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"}]},{"given":"Sushruta S.","family":"Nagarkatti","sequence":"first","affiliation":[{"name":"Thyroid Cancer Research Laboratory (M.A.N., C.N., S.S.N., D.M.-G., R.A.H. S.P.), Endocrine Surgery Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"}]},{"given":"Peter M.","family":"Sadow","sequence":"first","affiliation":[{"name":"Department of Pathology (P.M.S.), Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"}]},{"given":"Dieter","family":"Morales-Garcia","sequence":"first","affiliation":[{"name":"Thyroid Cancer Research Laboratory (M.A.N., C.N., S.S.N., D.M.-G., R.A.H. S.P.), Endocrine Surgery Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"}]},{"given":"Richard A.","family":"Hodin","sequence":"first","affiliation":[{"name":"Thyroid Cancer Research Laboratory (M.A.N., C.N., S.S.N., D.M.-G., R.A.H. S.P.), Endocrine Surgery Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"}]},{"given":"Sareh","family":"Parangi","sequence":"first","affiliation":[{"name":"Thyroid Cancer Research Laboratory (M.A.N., C.N., S.S.N., D.M.-G., R.A.H. S.P.), Endocrine Surgery Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"}]}],"member":"80","reference":[{"key":"2020071612182979500_B1","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.ecl.2008.02.003","article-title":"Anaplastic thyroid cancer.","volume":"37","author":"Neff","year":"2008","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2020071612182979500_B2","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1245\/ASO.2006.05.042","article-title":"Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches.","volume":"13","author":"Are","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"2020071612182979500_B3","doi-asserted-by":"crossref","first-page":"563","DOI":"10.4158\/EP09106.CRR","article-title":"Anaplastic thyroid cancer manifesting as new-onset Horner syndrome.","volume":"15","author":"Broome","year":"2009","journal-title":"Endocr Pract"},{"key":"2020071612182979500_B4","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/00001622-200301000-00012","article-title":"Anaplastic thyroid cancer.","volume":"15","author":"Pasieka","year":"2003","journal-title":"Curr Opin Oncol"},{"key":"2020071612182979500_B5","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1210\/jc.2002-021863","article-title":"Clinical review 158: Beyond radioiodine: a review of potential new therapeutic approaches for thyroid cancer.","volume":"88","author":"Braga-Basaria","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612182979500_B6","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1001\/archsurg.142.8.717","article-title":"Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma.","volume":"142","author":"Wiseman","year":"2007","journal-title":"Arch Surg"},{"key":"2020071612182979500_B7","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1385\/EP:15:4:319","article-title":"Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas.","volume":"15","author":"Nikiforov","year":"2004","journal-title":"Endocr Pathol"},{"key":"2020071612182979500_B8","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1210\/er.2007-0007","article-title":"BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.","volume":"28","author":"Xing","year":"2007","journal-title":"Endocr Rev"},{"key":"2020071612182979500_B9","doi-asserted-by":"crossref","first-page":"10649","DOI":"10.1073\/pnas.1004934107","article-title":"B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression.","volume":"107","author":"Nucera","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071612182979500_B10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1677\/ERC-08-0154","article-title":"Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies.","volume":"16","author":"Smallridge","year":"2009","journal-title":"Endocr Relat Cancer"},{"key":"2020071612182979500_B11","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1158\/0008-5472.CAN-09-0727","article-title":"Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.","volume":"69","author":"Ricarte-Filho","year":"2009","journal-title":"Cancer Res"},{"key":"2020071612182979500_B12","first-page":"152","article-title":"Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E).","volume":"1795","author":"Nucera","year":"2009","journal-title":"Biochim Biophys Acta"},{"key":"2020071612182979500_B13","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1073\/pnas.0711741105","article-title":"Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.","volume":"105","author":"Tsai","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071612182979500_B14","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/j.1755-148X.2009.00618.x","article-title":"Identification of direct transcriptional targets of (V600E)BRAF\/MEK signalling in melanoma.","volume":"22","author":"Packer","year":"2009","journal-title":"Pigment Cell Melanoma Res"},{"key":"2020071612182979500_B15","doi-asserted-by":"crossref","first-page":"20411","DOI":"10.1073\/pnas.0905833106","article-title":"MEK1 mutations confer resistance to MEK and B-RAF inhibition.","volume":"106","author":"Emery","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071612182979500_B16","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma.","volume":"363","author":"Flaherty","year":"2010","journal-title":"N Engl J Med"},{"key":"2020071612182979500_B17","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1210\/jc.2009-0373","article-title":"Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells.","volume":"95","author":"Salerno","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612182979500_B18","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1158\/0008-5472.CAN-10-3844","article-title":"BRAFV600E and microenvironment in thyroid cancer: a functional link to drive cancer progression.","volume":"71","author":"Nucera","year":"2011","journal-title":"Cancer Res"},{"key":"2020071612182979500_B19","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1089\/thy.2007.0097","article-title":"Molecular and genotypic characterization of human thyroid follicular cell carcinoma-derived cell lines.","volume":"17","author":"Meireles","year":"2007","journal-title":"Thyroid"},{"key":"2020071612182979500_B20","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1089\/thy.2009.0055","article-title":"A novel orthotopic mouse model of human anaplastic thyroid carcinoma.","volume":"19","author":"Nucera","year":"2009","journal-title":"Thyroid"},{"key":"2020071612182979500_B21","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1634\/theoncologist.2010-0317","article-title":"Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer.","volume":"16","author":"Nucera","year":"2011","journal-title":"Oncologist"},{"key":"2020071612182979500_B22","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1200\/JCO.2008.16.3279","article-title":"Phase II trial of sorafenib in advanced thyroid cancer.","volume":"26","author":"Gupta-Abramson","year":"2008","journal-title":"J Clin Oncol"},{"key":"2020071612182979500_B23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1056\/NEJMoa075853","article-title":"Motesanib diphosphate in progressive differentiated thyroid cancer.","volume":"359","author":"Sherman","year":"2008","journal-title":"N Engl J Med"},{"key":"2020071612182979500_B24","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1200\/JCO.2008.18.2717","article-title":"Phase II trial of sorafenib in metastatic thyroid cancer.","volume":"27","author":"Kloos","year":"2009","journal-title":"J Clin Oncol"},{"key":"2020071612182979500_B25","doi-asserted-by":"crossref","first-page":"4708","DOI":"10.1200\/JCO.2007.15.9566","article-title":"Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.","volume":"26","author":"Cohen","year":"2008","journal-title":"J Clin Oncol"},{"key":"2020071612182979500_B26","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer.","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"2020071612182979500_B27","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1200\/JCO.2008.20.1426","article-title":"BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer.","volume":"27","author":"Xing","year":"2009","journal-title":"J Clin Oncol"},{"key":"2020071612182979500_B28","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1677\/ERC-07-0212","article-title":"BRAF(V600E) mutation and the biology of papillary thyroid cancer.","volume":"15","author":"Frasca","year":"2008","journal-title":"Endocr Relat Cancer"},{"key":"2020071612182979500_B29","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1158\/0008-5472.CAN-05-0047","article-title":"Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation.","volume":"65","author":"Knauf","year":"2005","journal-title":"Cancer Res"},{"key":"2020071612182979500_B30","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature08833","article-title":"RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.","volume":"464","author":"Hatzivassiliou","year":"2010","journal-title":"Nature"},{"key":"2020071612182979500_B31","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.cell.2009.12.040","article-title":"Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.","volume":"140","author":"Heidorn","year":"2010","journal-title":"Cell"},{"key":"2020071612182979500_B32","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nature08902","article-title":"RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.","volume":"464","author":"Poulikakos","year":"2010","journal-title":"Nature"},{"key":"2020071612182979500_B33","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1038\/onc.2011.44","article-title":"Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGF\u03b2 signaling.","volume":"30","author":"Knauf","year":"2011","journal-title":"Oncogene"},{"key":"2020071612182979500_B34","doi-asserted-by":"crossref","first-page":"13138","DOI":"10.1073\/pnas.231487798","article-title":"Expression of cyclins E1 and E2 during mouse development and in neoplasia.","volume":"98","author":"Geng","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071612182979500_B35","doi-asserted-by":"crossref","first-page":"751","DOI":"10.18632\/oncotarget.210","article-title":"The BRAFV600E mutation: what is it really orchestrating in thyroid cancer?","volume":"1","author":"Nucera","year":"2010","journal-title":"Oncotarget"},{"key":"2020071612182979500_B36","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1210\/jc.2006-2707","article-title":"BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism.","volume":"92","author":"Durante","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612182979500_B37","doi-asserted-by":"crossref","first-page":"8317","DOI":"10.1158\/0008-5472.CAN-09-1248","article-title":"The BRAFV600E oncogene induces transforming growth factor \u03b2 secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.","volume":"69","author":"Riesco-Eizaguirre","year":"2009","journal-title":"Cancer Res"}],"container-title":["Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/endo\/article-pdf\/153\/2\/985\/10389651\/endo0985.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/endo\/article-pdf\/153\/2\/985\/10389651\/endo0985.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T15:49:49Z","timestamp":1594914589000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/endo\/article\/153\/2\/985\/2424566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,1]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2,1]]}},"URL":"https:\/\/doi.org\/10.1210\/en.2011-1519","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.13945990.15401097","asserted-by":"object"}]},"ISSN":["0013-7227","1945-7170"],"issn-type":[{"value":"0013-7227","type":"print"},{"value":"1945-7170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,1]]}}}